The primary resistance of HCC cells to sorafenib is postulated to be associated with genetic heterogeneity—the overexpression of epidermal growth factor receptor (EGFR) or ligand may lead to sustained activation of EGFR downstream signaling and drug resistance to sorafenib [6,7]. Here, EGFR is linked to hepatocellular carcinoma.